Project Grant R01HL173989
Award Date
8/1/24
Completion Date
4/30/28
Dollars Obligated
$693K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $650,020.00 to Loyola University of Chicago's Health Sciences Campus to investigate the structural and functional basis of myocardial dysregulation in genetic cardiomyopathies. The 4-year project aims to determine the impact of hypertrophic (HCM) and dilated (DCM) cardiomyopathy gene variants on normal sarcomere structure, the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) provides $719,462 to Baylor College of Medicine to develop a high-throughput variant interpretation approach for the MYH7 gene, which is broadly applicable to other cardiomyopathies and genetic diseases. The key products and services to be delivered include: Developing an integrase-based system for high-throughput variant molecular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on understanding the molecular mechanisms behind diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The key objectives are to: 1) fully characterize the specific functional domains of the cardiac thin filament linked to the regulation of cardiac relaxation, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $579,425 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Case Western Reserve University (CWRU) to develop and improve the delivery of gene therapy treatments, including adeno-associated viral (AAV) and nanoparticle (NP) therapies, to the heart. The goal is to enhance the efficacy and safety of these therapies for treating cardiomyopathies, which are highly prevalent disorders of the cardiac muscle that often...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Washington (UW) with a performance period from December 20, 2024 to November 30, 2026. The objective of this grant is to establish a high-throughput in vitro model using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to assess the functional effects of MYH7 gene variants associated with hypertrophic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $777,258 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on improving the understanding of heart failure in patients with hypertrophic cardiomyopathy. The project aims to leverage advanced cardiac magnetic resonance imaging (CMR) techniques, including exercise CMR, to characterize the underlying...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $756,039 to the Regents of the University of Michigan to conduct research on genetic factors that influence the severity of cardiomyopathies. The key objectives are to: 1) Quantify the gene expression effects of all possible single nucleotide variants (SNVs) in the cis-regulatory elements (CREs) of the MYBPC3 and DSP genes, which...
This Project Grant award of $678,445.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to investigate the role of the novel protein C5ORF51 (C5X) in regulating cardiomyocyte function and homeostasis. The overarching hypothesis is that C5X, as a modulator of core cardiac transcription factors, plays a critical role in cardiomyogenesis and maintaining normal cardiac function. The research project aims to...
This federal Project Grant award of $2,507,438.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to perform a deep mutational scan of the MYH7 gene in human induced pluripotent stem cell-derived cardiomyocytes. The key objectives are to: 1) Generate a single nucleotide variant library of nearly all possible MYH7 variants in these cells using a novel CRISPR-based gene editing technique, and 2) Develop...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support a $135,840 research initiative at the University of Washington to investigate the mechanisms of cardiac contractile dysfunction across multiple biological scales. The overarching goal is to establish a framework for understanding how structural perturbations to the myosin protein affect its interaction with actin, a key driver of...